Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary-Elizabeth Percival

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Leukemia|July 31, 2023
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasmsLauren Shih, Megan Othus, Kelda Schonhoff, et al.
Leukemia & Lymphoma|December 21, 2020
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Leukemia & Lymphoma|October 3, 2018
A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off studySarah A Buckley, Mary-Elizabeth Percival, Megan Othus, et al.
Journal of Human Genetics|May 17, 2013
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemiaSook Wah Yee, Joel A Mefford, Natasha Singh, et al.
Journal of Neuro-Oncology|January 20, 2024
Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS controlMaryam Ebadi, Margaret Morse, Ted Gooley, et al.
Transplantation and Cellular Therapy|November 27, 2022
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice GuidelinesZachariah DeFilipp, Stefan O Ciurea, Corey Cutler, et al.
Haematologica|March 3, 2022
Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapyFrancesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Blood Advances|October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 studyJessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Leukemia|July 31, 2023
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasmsLauren Shih, Megan Othus, Kelda Schonhoff, et al.
Leukemia & Lymphoma|December 21, 2020
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Leukemia & Lymphoma|October 3, 2018
A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off studySarah A Buckley, Mary-Elizabeth Percival, Megan Othus, et al.
Journal of Human Genetics|May 17, 2013
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemiaSook Wah Yee, Joel A Mefford, Natasha Singh, et al.
Journal of Neuro-Oncology|January 20, 2024
Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS controlMaryam Ebadi, Margaret Morse, Ted Gooley, et al.
Transplantation and Cellular Therapy|November 27, 2022
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice GuidelinesZachariah DeFilipp, Stefan O Ciurea, Corey Cutler, et al.
Haematologica|March 3, 2022
Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapyFrancesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Blood Advances|October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 studyJessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Pageof 3